PMID- 38410235
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240229
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 13
IP  - 1
DP  - 2024 Jan 31
TI  - Fusion of NY-ESO-1 epitope with heat shock protein 70 enhances its induced immune 
      responses and antitumor activity against glioma in vitro.
PG  - 191-201
LID - 10.21037/tcr-23-1476 [doi]
AB  - BACKGROUND: Glioma is the most common tumor originating in the brain and is 
      difficult to cure. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a 
      promising cancer testis antigen (CTA) for tumor immunotherapy, and heat shock 
      proteins (HSPs) can promote the antigen presentation of chaperoned peptides. This 
      study investigates the therapeutic potential of HSP70 and NY-ESO-1 epitope fusion 
      protein for glioma. METHODS: Recombinant HSP70 protein was purified and fused to 
      NY-ESO-1 epitope to generate HSP70/NY-ESO-1 p86-94. NY-ESO-1 expression was 
      induced in U251 glioma cells via 5-Aza-2'-deoxycytidine (5-Aza-CdR) treatment. 
      Dendritic cells (DCs) loaded with HSP70/NY-ESO-1 p86-94 or NY-ESO-1 protein 
      stimulated NY-ESO-1-specific cytotoxic T lymphocytes (CTLs). The killing effect 
      of NY-ESO-1 specific CTLs on U251 cells was detected by lactate dehydrogenase 
      (LDH). RESULTS: 5-Aza-CdR successfully induced NY-ESO-1 expression in U251 cells. 
      NY-ESO-1-stimulated CTLs lysed more significantly with NY-ESO-1-positive U251 
      cells than with NY-ESO-1-negative cells. The immune response stimulated by a 
      DC-based vaccine of HSP70/NY-ESO-1 p86-94 fusion protein was significantly 
      enhanced compared with that induced by NY-ESO-1 alone. CONCLUSIONS: These 
      findings indicate that the HSP70/NY-ESO-1 p86-94 may significantly enhance 
      CTLs-mediated cytotoxicity and targeting ability against NY-ESO-1-expressing 
      tumors in vitro. 5-Aza-CdR treatment with HSP70 binding to tumor antigen is a new 
      strategy for immunotherapy of the tumors with poor CTA expression.
CI  - 2024 Translational Cancer Research. All rights reserved.
FAU - Chen, Yuqing
AU  - Chen Y
AD  - Department of Pathology and Institute of Oncology, School of Basic Medical 
      Science, Fujian Medical University, Fuzhou, China.
AD  - Diagnostical Pathology Center, Fujian Medical University, Fuzhou, China.
FAU - Zheng, Lin
AU  - Zheng L
AD  - Department of Pathology and Institute of Oncology, School of Basic Medical 
      Science, Fujian Medical University, Fuzhou, China.
AD  - Diagnostical Pathology Center, Fujian Medical University, Fuzhou, China.
FAU - Hua, Wenxi
AU  - Hua W
AD  - Department of Pathology and Institute of Oncology, School of Basic Medical 
      Science, Fujian Medical University, Fuzhou, China.
AD  - Diagnostical Pathology Center, Fujian Medical University, Fuzhou, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Pathology and Institute of Oncology, School of Basic Medical 
      Science, Fujian Medical University, Fuzhou, China.
AD  - Diagnostical Pathology Center, Fujian Medical University, Fuzhou, China.
FAU - Chen, Lihong
AU  - Chen L
AD  - Department of Pathology and Institute of Oncology, School of Basic Medical 
      Science, Fujian Medical University, Fuzhou, China.
AD  - Diagnostical Pathology Center, Fujian Medical University, Fuzhou, China.
FAU - Huang, Aimin
AU  - Huang A
AD  - Department of Pathology and Institute of Oncology, School of Basic Medical 
      Science, Fujian Medical University, Fuzhou, China.
AD  - Diagnostical Pathology Center, Fujian Medical University, Fuzhou, China.
FAU - Zhang, Wenmin
AU  - Zhang W
AD  - Department of Pathology and Institute of Oncology, School of Basic Medical 
      Science, Fujian Medical University, Fuzhou, China.
AD  - Diagnostical Pathology Center, Fujian Medical University, Fuzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20240119
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC10894325
OTO - NOTNLM
OT  - 5-Aza-2'-deoxycytidine (5-Aza-CdR)
OT  - New York esophageal squamous cell carcinoma 1 (NY-ESO-1)
OT  - dendritic cell (DC)
OT  - glioma
OT  - heat shock protein 70 (HSP70)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://tcr.amegroups.com/article/view/10.21037/tcr-23-1476/coif). All authors 
      report that the work was supported by grants from National Natural Science 
      Foundation of China (No. 81472830) and Natural Science Foundation of Fujian 
      Province (Nos. 2018J01835, 2022J01202). The authors have no other conflicts of 
      interest to declare.
EDAT- 2024/02/27 06:44
MHDA- 2024/02/27 06:45
PMCR- 2024/01/31
CRDT- 2024/02/27 03:36
PHST- 2023/08/15 00:00 [received]
PHST- 2023/11/29 00:00 [accepted]
PHST- 2024/02/27 06:45 [medline]
PHST- 2024/02/27 06:44 [pubmed]
PHST- 2024/02/27 03:36 [entrez]
PHST- 2024/01/31 00:00 [pmc-release]
AID - tcr-13-01-191 [pii]
AID - 10.21037/tcr-23-1476 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2024 Jan 31;13(1):191-201. doi: 10.21037/tcr-23-1476. Epub 
      2024 Jan 19.